{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:47:34Z","timestamp":1792932454580,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olorinab is a highly selective, peripherally acting, full agonist of cannabinoid receptor 2. This study assessed the efficacy and safety of olorinab to treat abdominal pain in patients with irritable bowel syndrome with diarrhea (IBS\u2010D) and constipation (IBS\u2010C).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CAPTIVATE was a phase 2b, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group trial. Eligible participants aged 18\u201370\u2009years with IBS\u2010C and IBS\u2010D diagnosed per Rome IV received olorinab 10\u00a0mg, 25\u2009mg, or 50\u2009mg three times daily (TID) or placebo TID for 12\u2009weeks. The primary endpoint was the change in patient\u2010reported average abdominal pain score (AAPS) from baseline to Week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      A total of 273 participants were randomized to receive olorinab 10\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a067), olorinab 25\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a067), olorinab 50\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a069), or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a070). Although a treatment response was observed across all groups, the weekly change in average AAPS from baseline to Week 12 was not significantly different between placebo and any olorinab dose. In a prespecified subgroup analysis of participants with a baseline AAPS \u22656.5, olorinab 50\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a035) significantly improved AAPS compared with placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a030) (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.014). Adverse event rates were comparable between olorinab and placebo and there were no reported serious adverse events or deaths.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Inferences<\/jats:title>\n                    <jats:p>\n                      Although olorinab was well\u2010tolerated and improved weekly AAPS, the primary endpoint was not met. However, in participants with moderate\u2010to\u2010severe pain at baseline (AAPS \u22656.5), olorinab 50\u2009mg significantly improved weekly AAPS compared with placebo.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      : NCT04043455.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/nmo.14539","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T01:20:00Z","timestamp":1675646400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo\u2010controlled trial (\n                    <scp>CAPTIVATE<\/scp>\n                    )"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-2967","authenticated-orcid":false,"given":"Lin","family":"Chang","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine UCLA  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-1188","authenticated-orcid":false,"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kunkel","sequence":"additional","affiliation":[{"name":"University of California San Diego  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"English","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Lindstrom","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibao","family":"Gu","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Skare","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye","family":"Gilder","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Turner","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cataldi","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lipkis","sequence":"additional","affiliation":[{"name":"Sharp Grossmont Hospital  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.014"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640617731968"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6110099"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32115-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.032"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm17137"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6759"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17718677"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16484"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.78"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00404.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000502"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14305"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6110101"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.42747"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.07.028"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.026"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13688"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0071599"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90285.2008"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707486"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00396"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002314"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaa089"},{"key":"e_1_2_11_26_1","unstructured":"SchmielS LindstromB GuG MillerP MironY AdamsJ.Olorinab a peripherally acting highly selective full agonist of the cannabinoid receptor 2 (CB2) reduces calcium influx following TRPV1 activation in human visceral nociceptors. Paper Presented at: IASP 2021 Virtual World Congress on Pain; Virtual."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543401003777995"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04144.x"},{"key":"e_1_2_11_30_1","unstructured":"US Center for Drug Evaluation and Research;Guidance for industry irritable bowel syndrome\u2014clinical evaluation of drugs for treatment. US Center for Drug Evaluation and Research. Updated 05\/2012. Accessed March 28 2022.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM205269.pdf"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13774"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12264"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13081"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00023-6"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.025"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2014.20.2.163"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00797"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04730.x"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.03.018"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4099-11.2011"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2010.0407"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.06.031"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.009"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.641436"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.08.025"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nmo.14539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/nmo.14539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nmo.14539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T20:33:36Z","timestamp":1692563616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nmo.14539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/nmo.14539"],"URL":"https:\/\/doi.org\/10.1111\/nmo.14539","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,5]]},"assertion":[{"value":"2022-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14539"}}